Retinol is a cornerstone of anti-aging dermatology, recognized for its ability to stimulate collagen biosynthesis and accelerate epidermal turnover. However, its clinical application is often limited by dose-dependent adverse effects such as erythema and dryness, and more recently, by Regulation (EU) 2024/996, which restricts retinol concentration in topical cosmetics to a maximum of 0.3%. To address these regulatory and tolerability challenges, researchers evaluated Retinduo®, a technology combining 0.3% retinol with 0.05% encapsulated retinal and natural boosters like phytol and apigenin. This solution aims to maintain the high efficacy associated with 0.5% retinol while ensuring regulatory compliance and maximizing skin tolerance through advanced delivery systems.
Methods
This 3-month, randomized, double-blind study compared Retinduo® to a 0.5% retinol serum in 40 women with moderate photoaging. Participants followed a progressive application protocol and underwent periodic clinical and instrumental assessments. Evaluations included measurements of hydration, firmness, wrinkle depth, melanin levels, and stratum corneum thickness. Statistical analysis utilized paired t-tests and Wilcoxon tests to determine significant changes from baseline.
Key Findings
- Comparable Core Efficacy: Both Retinduo® and 0.5% retinol significantly improved hydration, firmness, and elasticity by day 28.
- Superior Viscoelasticity: Retinduo® achieved a significant increase in viscoelasticity (R8) at day 56, a parameter where 0.5% retinol did not show significant changes.
- Advanced Wrinkle Reduction: Significant wrinkle depth reduction was observed with Retinduo® at day 28, outperforming the non-significant positive trends seen with 0.5% retinol.
- Enhanced Skin Renewal: Retinduo® induced a 30% reduction in stratum corneum thickness by month three, significantly higher than the 12% reduction achieved by the 0.5% retinol group.
- Excellent Tolerance: Both formulations exhibited very good cutaneous tolerability with minimal, typical retinoid-related irritation and over 90% patient satisfaction.
The novelty of this research lies in being the first randomized trial to demonstrate that a synergistic retinoid combination (retinol 0.3% + retinal 0.05%) can match or exceed the performance of higher-concentration retinol while adhering to strict new European safety standards. This is achieved through a “smart formulation” that uses encapsulation and natural boosters to maximize biological activity and ingredient penetration. The future implications of this study are significant, as it provides a validated roadmap for developing high-performance anti-aging products that prioritize both clinical results and regulatory safety.
Link to the study: https://www.mdpi.com/2079-9284/13/3/133
Photographs obtained with C-Cube® reconstruct 3D images by analyzing multiple images captured under different lighting conditions. In the example, skin treated with retinol 0.5% (above) is compared to Retinduo® 0.5% (below), from the beginning to the end of the study.